For research use only. Not for therapeutic Use.
CCT369260 (CAT: I045989) is an orally active B-cell lymphoma 6 (BCL6) inhibitor with demonstrated antitumor potential. It effectively disrupts BCL6 transcriptional repression, exhibiting an IC₅₀ of 520 nM, making it a potent tool for studying oncogenic signaling. In vivo, a single oral dose of 15 mg/kg significantly inhibited BCL6 activity in the OCI-Ly1 diffuse large B-cell lymphoma (DLBCL) xenograft model, highlighting its therapeutic relevance. By selectively targeting BCL6, a master regulator of germinal center B-cell survival, CCT369260 provides a valuable probe for investigating BCL6-driven lymphomas and supports preclinical development of novel cancer therapies.
| CAS Number | 2647503-57-7 |
| Synonyms | 5-[[5-chloro-2-[(3R,5S)-4,4-difluoro-3,5-dimethylpiperidin-1-yl]pyrimidin-4-yl]amino]-3-(3-hydroxy-3-methylbutyl)-1-methylbenzimidazol-2-one |
| Molecular Formula | C24H31ClF2N6O2 |
| Purity | ≥95% |
| IUPAC Name | 5-[[5-chloro-2-[(3R,5S)-4,4-difluoro-3,5-dimethylpiperidin-1-yl]pyrimidin-4-yl]amino]-3-(3-hydroxy-3-methylbutyl)-1-methylbenzimidazol-2-one |
| InChI | InChI=1S/C24H31ClF2N6O2/c1-14-12-32(13-15(2)24(14,26)27)21-28-11-17(25)20(30-21)29-16-6-7-18-19(10-16)33(22(34)31(18)5)9-8-23(3,4)35/h6-7,10-11,14-15,35H,8-9,12-13H2,1-5H3,(H,28,29,30)/t14-,15+ |
| InChIKey | VFNPUAOAEFMXQI-GASCZTMLSA-N |
| SMILES | CC1CN(CC(C1(F)F)C)C2=NC=C(C(=N2)NC3=CC4=C(C=C3)N(C(=O)N4CCC(C)(C)O)C)Cl |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
